Population pharmacokinetics of ustekinumab in patients with active psoriatic arthritis

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 12, 2010, Pages 830-846

  Zhu, Y W ^a   Mendelsohn, A ^a   Pendley, C ^a   Davis, H M ^a   Zhou, H ^a  

^a CENTOCOR INC   (United States)

Author keywords

Interleukin 12 23 p40; Monoclonal antibody; Population pharmacokinetics; Psoriatic arthritis; Ustekinumab

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; USTEKINUMAB;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION DISTRIBUTION; PREDICTIVE VALUE; PROCESS MODEL; PSORIATIC ARTHRITIS; STATISTICAL MODEL; VALIDATION PROCESS;

EID: 78650802869     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48830     Document Type: Article

References (43)

1. Stelara [package insert]. Horsham, PA: Centocor Ortho Biotech Inc.; 2009.
2. Akaike H. A Bayesian analysis of the minimum AIC procedure. Ann Inst Statist Math. 1978; 30: 9-14.
3. Antoni C, Krueger GG, de Vlam K et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005; 64: 1150-1157. (Pubitemid 41113349)
4. Antoni CE, Kavanaugh A, Kirkham B et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005; 52: 1227-1236.
5. Beal SL. Ways to fit a PKmodel with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001; 28: 481-504.
6. Boeckmann AJ, Sheiner LB, Beal SL. NONMEM Users Guide: Part VIII. San Francisco: Regents of the University of California; 2008.
7. Chan JR, Blumenschein W, Murphy E et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006; 203: 2577-2587.
8. Genovese MC, Mease PJ, Thomson GT et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol. 2007; 34: 1040-1050.
9. Gladman DD, Antoni C, Mease P et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005; 64 (Suppl 2): ii14-ii17.
10. Gladman DD, Mease PJ, Cifaldi MA et al. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the adalimumab effectiveness in psoriatic arthritis trial. Ann Rheum Dis. 2007; 66: 163-168.
11. Gorski JC, Hall SD, Becker P et al. In vivo effects of interleukin-10 on human cytochrome P450 activity. Clin Pharmacol Ther. 2000; 67: 32-43.
12. Gottlieb A, Menter A, Mendelsohn A et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009; 373: 633-640.
13. Gottlieb AB, Cooper KD, McCormick TS et al. A phase I, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr Med Res Opin. 2007; 23: 1081-1092.
14. Griffiths CE, Strober BE, van de Kerkhof P et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.NEngl J Med. 2010; 362: 118-128.
15. Kauffman CL, Aria N, Toichi E et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol. 2004; 123: 1037-1044.
16. Kavanaugh A, Antoni C, Krueger GG et al. Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Ann Rheum Dis. 2006; 65: 471-477.
17. Kavanaugh A, McInnes I, Mease P et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009; 60: 976-986.
18. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996; 14: 485-496. (Pubitemid 26249398)
19. Krueger GG, Langley RG, Leonardi C et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007; 356: 580-592.
20. Langrish CL, Chen Y, Blumenschein WM et al. IL-23 drives a pathogenic Tcell population that induces autoimmune inflammation. J Exp Med. 2005; 201: 233-240.
21. Lebwohl M, Yeilding N, Szapary P et al. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendations. J Am Acad Dermatol. 2010; doi: 10.1016/j.jaad.2009.11.012.
22. Leonardi CL, Kimball AB, Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008; 371: 1665-1674.
23. Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003; 349: 2014-2022.
24. Mease PJ, Gladman DD, Ritchlin CT et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005; 52: 3279-3289.
25. Mease PJ, Kivitz AJ, Burch FX et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004; 50: 2264-2272.
26. Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther. 2009; 85: 434-438.
27. Nestorov I, Zitnik R, Ludden T. Population pharmacokinetic modeling of subcutaneously administered etanercept in patients with psoriasis. J Pharmacokinet Pharmacodyn. 2004; 31: 463-490.
28. Ng CM, Bruno R, Combs D et al. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol. 2005; 45: 792-801.
29. Papp KA, Langley RG, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008; 371: 1675-1684.
30. Parke J, Holford NH, Charles BG. Aprocedure for generating bootstrap samples for the validation of nonlinearmixed-effects populationmodels. Comput Methods Programs Biomed. 1999; 59: 19-29. (Pubitemid 29125558)
31. Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderateto-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005; 366: 1367-1374.
32. Ribbens C, Andre B, Kaye O et al. Increased synovial fluid levels of interleukin-12, sCD25 and sTNF-RII/sTNF-RI ratio delineate a cytokine pattern characteristic of immune arthropathies. Eur Cytokine Netw. 2000; 11: 669-676.
33. Schwarz G. Estimating the dimension of a model. Ann Stat. 1978; 6: 461-464.
34. Seitz K, Zhou H. Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check. J Clin Pharmacol. 2007; 47: 1104-1118.
35. Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol. 2001; 28: 1842-1846.
36. Sun YN, Lu JF, Joshi Aet al. Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects. J Clin Pharmacol. 2005; 45: 468-476.
37. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008; 84: 548-558.
38. Wong K, Gladman DD, Husted J et al. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum. 1997; 40: 1868-1872.
39. Xu Z, Vu T, Lee H et al. Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis. J Clin Pharmacol. 2009; 49: 1056-1070.
40. Zhou H. Population-based assessments of clinical drug-drug interactions: qualitative indices or quantitative measures? J Clin Pharmacol. 2006; 46: 1268-1289.
41. Zhou H, Hu C, Zhu Y et al. Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2010; 50: 257-267.
42. Zhu Y, Hu C, Lu M et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2009; 49: 162-175.
43. Zhu Y, Yan H, Yeilding N et al. Exposure-response relationship of ustekinumab in two phase III studies in patients with moderate-to-severe plaque psoriasis. AAPS J. 2009; 11 (S2): 2128.